Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.59 |
| ▸ | CTSK | P43235 | 6/20 | 0.59 |
| ▸ | MME | P08473 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895414 | 1.00 | CTSS (0.59) | CTSSCTSKMMEATMMMEL1 | |
| SCHEMBL17050 | 1.00 | CTSS (0.59) | CTSSCTSKMMEATMMMEL1 | |
| SCHEMBL28132845 | 0.88 | ATM (0.60) | CTSSCTSKMMEATMAPP | |
| SCHEMBL1519889 | 0.88 | ATM (0.56) | CTSSCTSKMMEATMAPP | |
| SCHEMBL29163523 | 0.88 | ATM (0.56) | CTSSCTSKMMEATMAPP | |
| SCHEMBL7897952 | 0.88 | ATM (0.56) | CTSSCTSKATMAPPACE | |
| SCHEMBL489489 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPACE | |
| SCHEMBL1519945 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPACE | |
| SCHEMBL489490 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPACE | |
| SCHEMBL31494614 | 0.87 | CTSS (0.54) | CTSSCTSKMMEATMAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217440-B | Preparation method of sitagliptin key intermediate | 浙江永太手心医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| CN-116217440-A | Preparation method of sitagliptin key intermediate | 浙江永太手心医药科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-106478460-B | A kind of synthetic method of chirality N-Boc-3- amino -4- aryl-butyric acid | 衢州学院 | 2018-06-12 | — | — | CN | disclosed |
| CN-106478460-A | A kind of synthetic method of 3 amino of chirality N Boc, 4 aryl butyric acid | 衢州学院 | 2017-03-08 | — | — | CN | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| CN-101001841-A | Tetrahydroquinolones and aza-analogues thereof useful as DPP-IV inhibitors for the treatment of diabetes | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1758863-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | AstraZeneca AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | CTSS 2636/4885CTSK 3323/4885MME 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.